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Abstract
Background: Due to the widespread abusage of antibiotics, antibiotic-resistance in Streptococcus
pneumoniae (S. pneumoniae) has been increasing quickly in recent years, and it is obviously urgent
to develop new types of antibiotics. Two-component systems (TCSs) are the major signal
transduction pathways in bacteria and have emerged as potential targets for antibacterial drugs.
Among the 13 pairs of TCSs proteins presenting in S. pneumoniae, VicR/K is the unique one
essential for bacterium growth, and block agents to which, if can be found, may be developed as
effective antibiotics against S. pneumoniae infection.
Results:  Using a structure-based virtual screening (SBVS) method, 105 compounds were
computationally identified as potential inhibitors of the histidine kinase (HK) VicK protein from the
compound library SPECS. Six of them were then validated in vitro to be active in inhibiting the
growth of S. pneumoniae without obvious cytotoxicity to Vero cell. In mouse sepsis models, these
compounds are still able to decrease the mortality of the mice infected by S. pneumoniae and one
compound even has significant therapeutic effect.
Conclusion: To our knowledge, these compounds are the first reported inhibitors of HK with
antibacterial activity in vitro and in vivo, and are novel lead structures for developing new drugs to
combat pneumococcal infection.
Background
S. pneumoniae is a major risk factor with high morbidity
and mortality world-widely, especially in the elderly and
children. It is believed to be one of the four major infec-
tious disease killers [1-5]. Meanwhile, an increasing
number of bacterial strains with resistance are encoun-
tered in the clinic nowadays, among which antibiotic-
resistant S. pneumoniae has caused many deaths due to
antibiotics abusage in hospitals. Therefore, it is urgent to
develop new types of antibiotics.
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In prokaryotes, the two-component signaling systems
(TCSs), each pair of which are typically composed of his-
tidine kinase (HK) and response regulator (RR), play
important roles in drug-resistance, pathogenesis and bac-
terial growth [6-8]. The regulation of TCS on histidine
phosphorylation in signal transduction distinct from that
on serine/threonine and tyrosine phosphorylation in
higher eukaryotes [9]. For some TCSs, both the HK and RR
are essential for bacterial viability in several Gram-posi-
tive pathogens, including Bacillus subtilis (B. subtilis), Ente-
rococcus faecalis and Staphylococcus aureus (S. aureus) [10-
13], and thus received attention as potential targets for
antimicrobials [9,14-17]. In S. pneumoniae, although at
least 13 TCSs were identified, only TCS02 (also designated
as VicR/K [18], MicA/B [19] or 492 hk/rr [20]) is essential
for bacteria viability, which can be a potential target for
antimicrobial intervention. To be detailed, in TCS02, only
functional VicR appears to be essential for S. pneumoniae
[21], without which S. pneumoniae can't grow or act as a
pathogen [22]. However, the crystal structure of VicR is
unsuitable for structure-based virtual screening because
the active site is too shallow to dock a small molecule
[22,23]. The reason that VicK does not seem to be essen-
tial for S. pneumoniae viability, was supposed to be that
some currently unknown HKs also participate in the acti-
vation of VicR by phosphorylation [24,25]. However,
among these HKs, VicK it is best-known one with definite
action on VicR. Moreover, recent researches showed a
high-degree homology in the catalytic domain of these
HKs [14-17]. Thus theoretically, selective inhibitors to
VicK, a representative of HKs, can interrupt the phospho-
rylation of VicR and ultimately reduce the viability of S.
pneumoniae.
The structure-based virtual screening (SBVS), an approach
used widely in drug design and discovery, possesses many
advantages, such as rapidness, economization, efficiency
and high-throughput. In the recent years, SBVS has
attracted great attention in developing innovative antimi-
crobial agents. A case in point is the discovery of a lead-
compound named diarylquinoline against Mycobacterium
tuberculosis [26]. Our study here was designed to search
the compound database for potential inhibitors targeting
the VicK protein of S. pneumoniae by using in silico and
experimentalmethods, which may provide much valuable
information to develop new antibiotics against pneumo-
coccal infection.
Results
Sequence analysis of the VicK TCS in S. pneumoniae
Domain analysis http://smart.embl.de/smart/
show_motifs.pl?ID=Q9S1J9 indicated that the VicK pro-
tein of S. pneumoniae contained one transmembrane seg-
ment and several domains: PAS, PAC, HisKA and
HATPase_c. Multi-alignment of the HATPase_c domain
sequences showed that in most bacteria the sequences
around the ATP binding site of VicK HKs are similar and
have four conserved motifs: the N box, G1 box, F box and
G2 box [27]. This high homology of ATP binding domain
of HKs in bacteria makes it reasonable to screen antibac-
terial agents by using this domain as a potential target
[16].
Compared with VicK HATPase_c domain in S. pneumoniae
(GenBank accession number: AAK75332.1), the most
homologous sequence in the structural Protein Data Bank
(PDB) was the similar domain of Thermotoga maritime
(PDB entry: 2c2a) [28], a TCS molecule, with 33%
sequence identity and 57% conservative replacements
(Figure 1). This domain is the entire cytoplasmic portion
of a sensor HK protein. The X-ray crystal structure of the
domain of Thermotoga maritima was therefore used as a
template for modeling the 3D structure of the VicK
HATPase_c domain of S. pneumoniae.
A 3D model of the VicK HATPase_c domain of S. 
pneumoniae
Based on the X-ray diffraction crystal structure of the
homologous domain of the Thermotoga maritima, a 3D
model for the VicK HATPase_c domain of S. pneumoniae
was constructed. Figure 2A shows the final structure of
this model that were checked and validated using struc-
ture analysis programs Prosa and Profile-3D [29]. This
model of 3D structure contains five stranded b-sheets and
four a-helices, which form a two-layered a/b sandwich
structure. Figure 2B indicates that the model superposed
well with the homologous domain of Thermotoga mar-
itima, with a root-mean-square deviation (RMSD) of the
Ca atoms being about 1.34 . The surface shape and gen-
eral electrostatic feature of the HATPase_c domain of VicK
were shown in Figure 2C. The ATP binding site consists of
a relatively hydrophobic inner cavity and a larger
hydrophilic outer cavity. Both cavities are connected by a
gorge-like channel, and are consisted of highly conserved
residues which can bind and fix the substrate. The inner
part lack of polar amino acid residues can accommodate
the adenosine, while the outer one rich in charged resi-
dues can bind the triphosphate.
Discovery of potential inhibitors of the S. pneumoniae 
VicK HK by virtual screening
The target site for high throughput virtual screening
(HTVS) was the ATP-binding pocket of the VicK
HATPase_c model of S. pneumoniae, which consisted of
residues within a radius of 4  around the ATP site. In the
primary screening, the database SPECS containing about
200,000 molecules was searched for potential binders
using the program DOCK4.0 [30,31]. Subsequently, struc-
tures ranked in the first 10,000 were re-scored by using the
Autodock 3.05 program [32]. As a result, about 200 mol-BMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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The sequence alignment of the HATPase_c domain of VicK in S. pneumoniae and 2c2a Figure 1
The sequence alignment of the HATPase_c domain of VicK in S. pneumoniae and 2c2a. The symbols below the 
alignment represent the similarity between two proteins. "*" denotes identical residues between two sequences, ":"means sim-
ilar residues, "." means a bit different and blank means completely different. Schematic alignment diagram was made by the pro-
gram ClustalX.
The modeled structure of the VicK HATPase_c domain of S. pneumoniae Figure 2
The modeled structure of the VicK HATPase_c domain of S. pneumoniae. (A) The solid ribbon representation of the 
structure model of the VicK HATPase_c domain. (B) Structure superposition of sketch of modeled VicK structure with the 
template. (C) Shape and surface features of the ATP-binding pocket of the VicK HATPase_c domain. The color denotes elec-
trostatic potential of the protein surface. The red and blue color show negative and positive charged potential respectively, and 
the white surface means neutral potential of non-polar hydrophobic residues. The ATP-binding pocket is divided into "inner" 
and "outer" parts. The loop covered on the pocket is shown as tube for the sake of clearly demonstrating the hydrophobic 
inner part. The outer part of pocket is hydrophilic because of many polar residues in the entrance of the pocket, including the 
polar loop structure. All the pictures were generated by PyMol http://www.pymol.org/.BMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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ecules were filtered out by these highly selective methods.
Finally, we manually selected 105 molecules according to
their molecular diversity, shape complementarities, and
the potential to form hydrogen bonds and hydrophobic
interactions in the binding pocket of the VicK HATPase_c
domain.
Inhibition of the VicK' protein ATPase activity in vitro
In order to confirm the interaction of the potential VicK
inhibitors with their putative target protein, we expressed
and purified His-tagged VicK' protein by using the pET28a
plasmid in BL21(DE3) as shown in Figure 3A. The kinase
activity of VicK' protein was measured by quantifying the
amount ATP remained in solution after the enzymatic
reaction (Figure 3B). These results indicated that the puri-
fied VicK' protein possessed the ATPase activity, which can
hydrolyze ATP in vitro. Using the purified active VicK', we
obtained 23 compounds from the 105 candidate inhibi-
tors which could decrease the ATPase activity of VicK' pro-
tein by more than 50%, indicating these compounds may
also be potential VicK inhibitors in S. pneumoniae.
Antimicrobial activities of potential VicK' inhibitor and 
Cytotoxicity of the antimicrobial compounds in vitro
We investigated the bactericidal activity of these 23 com-
pounds against S. pneumoniae using a standard minimal
bactericidal concentration assay (MIC) (Table 1). Six com-
pounds (Figure 4), each inhibiting the VicK' activity by
more than 50% (52.8%, 54.8%, 51.6%, 61.9%, 71.1%
and 68.8%, respectively) (Figure 5), could obviously
inhibit the growth of S. pneumoniae, with MIC values
below 200 mM. Moreover, their MIC values were positively
correlated with the corresponding IC50 (the concentration
of inhibiting 50% VicK' protein autophosphorylation)
values (r = 0.93), which indicates that the bactericidal
effects of these chemicals were realized by disrupting the
VicK/R TCS system in S. pneumoniae. Chemical structures
of these 6 compounds are shown in Figure 4, which
belong to three different classes of chemicals: one imida-
zole analogue, four furan derivatives and one derivative of
thiophene (Figure 4).
A 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium
bromide (MTT) assay was carried out on Vero cell line to
determine the CC50(concentration that induces a 50%
cytotoxicity effect) values of these compounds. As shown
in Table 1, the CC50 values of all these six compounds
were larger than 200 mM and than their respective MIC
values, indicating low cytotoxicity effects on Vero cell.
Collectively, these compounds inhibited bacterial growth
with low toxic effects.
Time- and concentration-dependent growth curve
While several compounds identified in our study could be
used as excellent drug leads in vitro, the best and most val-
uable ways would be in vivo validation. The following
(A) SDS-PAGE analysis of VicK' purification (B) Identification of kinase activity of VicK' protein in vitro Figure 3
(A) SDS-PAGE analysis of VicK' purification (B) Identification of kinase activity of VicK' protein in vitro. Variant 
amounts of VicK' proteins were added into reaction systems containing a constant ATP concentration (5 mM). Each assay was 
performed in quadruplicate and repeated three times. Luminescent output is inversely correlated with the concentration of the 
kinase.BMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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results of the time- and concentration-dependent effects
of the lead inhibitors on the growth of S. pneumoniae fur-
ther illustrated their antibacterial characteristics, and
would be an important guide for in vivo administration.
As shown in Figure 6, the similar curves of compounds 1,
2, 3 and 5 indicated that these compounds have signifi-
cant activity against S. pneumoniae at concentration of
about 200 mM, and this activity could last at least 8 hours.
The most efficient inhibitor identified was compound 6,
which had bactericidal effect against S. pneumoniae even at
concentration of as low as 0.2 mM. However, even at con-
centration of 400 mM, compound 4 was not likely to have
bactericidal effect, but it seemed to have delayed the mul-
tiplication of S. pneumoniae.
Therapeutic effects of the lead compounds in mouse S. 
pneumoniae infections
Mouse sepsis models by S. pneumoniae (ATCC 7466) were
successfully established by intraperitoneal injection of
100 ml S. pneumoniae (5 × 103 CFU/ml). Generally, these
Chemical structures of the compounds with inhibitive effects  on the growth of S. pneumoniae Figure 4
Chemical structures of the compounds with inhibi-
tive effects on the growth of S. pneumoniae. These six 
inhibitors belong to three different classes of chemical struc-
tures: one imidazole analogue (compound 6), four furan 
derivatives (compound 2, 3, 4 and 5) and one derivative of 
thiophene (compound 1).
Inhibition ratio of VicK' protein autophosphorylation by six  lead compounds with antibacterial effects (from the 23 com- pounds) Figure 5
Inhibition ratio of VicK' protein autophosphorylation 
by six lead compounds with antibacterial effects 
(from the 23 compounds). The inhibitory activities of the 
compounds for the ATPase activity of the VicK' protein was 
measured using the Kinase-Glo™ Luminescent Kinase Assay. 
Briefly, purified VicK' protein(6 mg/50 ml) was pre-incubated 
with compounds(final concentration, 200 mM) in a reaction 
buffer containing 40 mM Tris-HCl (pH 7.5), 20 mM MgCl2 
and 0.1 mg/ml BSA, at room temperature for 10 min. Then 
ATP (5 mM) was added for another incubation of 10 min at 
room temperature, and detected the rest amount of ATP.
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Table 1: Biological effects of six potential inhibitors of the VicK histidine kinase
Chemical inhibitor MIC (mM) MBC (mM) CC50 (mM) on Vero cell IC50 (mM) for VicK'
protein
Compound 1 100 >200 213 542.25
Compound 2 50 200 321.33 562.41
Compound 3 100 >200 274.22 502.63
Compound 4 200 >200 360 >1000
Compound 5 100 >200 516.17 598.11
Compound 6 0.28 25 392 32.60
PNC 0.02 2.0 undone undoneBMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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Time and concentration-dependent effects of the candidate compounds on the growth of S. pneumoniae in vitro Figure 6
Time and concentration-dependent effects of the candidate compounds on the growth of S. pneumoniae in 
vitro.BMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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mice began to die within 24 hours and couldn't survive
more than 48 hours unless they got appropriate therapeu-
tic treatments. For facilitation of comparisons between the
effects of these compounds and positive control (penicil-
lin), the concentration of penicillin used in this study
almost equaled to that of the lead compounds. To rule out
the direct antibacterial effects that may compromise with
the efficiency of this model, the lead compounds and pen-
icillin were administrated through caudal vein. As shown
in Figure 7, these compounds were able to decrease,
though slightly, the mortality of the infected mice in the
first 24 hours as compared to negative control (normal
sodium, NS) (p < 0.01). Significant treatment effects were
found among the groups (p < 0.01) by an overall compar-
ison. Pairwise comparisons revealed that compounds 1–6
prolonged survival time in mouse sepsis models as com-
pared to negative control (p < 0.01). However, compound
1, 2, 3 and 6 were less effective than positive control PNC
(p < 0.05 or p < 0.1). Although these compounds could
not reverse the fatal pneumococcal infection with concen-
tration used in this study, in vivo antibacterial activity of
these six compounds suggested that it would be promis-
ing to develop lead-compound-based drugs against pneu-
mococcal infection.
Molecular modeling of VicK' protein and its potential 
inhibitors
In order to get insight into the mechanism of inhibition,
further studies were carried out to verify the interaction
modes between six compounds and the modeled struc-
ture of VicK' protein. Autodock 3.05 software was used for
the docking simulation. The binding conformations of
these inhibitors in the ATP-binding pocket of the VicK
HATPase_c domain were shown in Figure 8. Although
these structures are diverse, the binding models of six
potential inhibitors are similar, especially in the inner part
of the conserved domain. The surface of the binding
pocket (Figure 2C) is divided into two parts, one is hydro-
phobic inner part composed of residues ILE146, ILE175,
LEU180, ILE182, PHE238, and the other is the outer
hydrophilic part consisted of residues ASN149, LYS152,
TYR153, ARG196, ARG199. All six compounds bind in
the pocket with rigid aromatic ring parts inserting into the
inner part. In the large and flexible outer part, these com-
Therapeutic efficacies of each lead compound against infection with S. pneumoniae ATCC7466 in mice Figure 7
Therapeutic efficacies of each lead compound against infection with S. pneumoniae ATCC7466 in mice. Figure 
shows the cumulative survival (survival probability) of the mouse infection models treated differently in the following 8 days 
(survival time more than 8 days was censored). Data were analyzed by using the survival analysis approach (Kaplan-Meier 
Method). Significant treatment effects were found among the groups (P < 0.01) by an overall comparison. Pairwise comparisons 
revealed that compounds 1–6 prolonged survival time in mouse infection models as compared to negative control (p < 0.01), 
and that compound 4 and 5 were almost as effective as positive control PNC (P > 0.1), but the other compounds were less 
effective than it (P < 0.05 or P < 0.1). *P < 0.01 indicates significant differences as compared to negative control; #P < 0.05 and 
$P < 0.1 indicate significant differences as compared to positive control.
Survival time after infection (h) BMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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pounds adopt different interactions. All of them have
hydrogen bond acceptors in the binding outer part. They
could form hydrogen networks with the polar residues to
stabilize the substrate interactions. Their binding models
resemble natural substrate ATP much.
Discussion
In bacteria, HKs have fundamental roles in TCS signal
transduction pathways. Thus they are major targets for
antibacterial drug development. High structural and
sequence homology of this kinase gene family makes the
HKs ideal targets for homology modeling and structure
based virtual screening. SBVS is an approach based on the
three-dimensional structures of macromolecular to iden-
tify chemical entities binding to the targets and to elicit
potential biological mechanisms with the advantages of
speed, efficiency and high-throughput. The availability of
the small molecular lead-compound library and the mod-
eled 3D target structure makes it possible to use SBVS to
screen out a limited number of promising candidates that
can interrupt the TCS signal transduction by interacting
with the HKs substrate of S. pneumoniae.
HKs, as novel antibacterial targets, have attracted many
attentions due to their essentiality in the viability of
microbes and their deficiency in animals. HKs are
involved in the regulation of bacterial growth and viru-
lence in many bacterial species. Previously, a HK named
VicK has been used to screen lead compound inhibitors in
B. subtilis and S. epidermidis. We here for the first time
obtained 105 candidate chemical compounds directly
aiming at S. pneumoniae VicK by screening 200,000 possi-
ble compounds in silico. Compounds that can bind to the
purified target protein VicK' and compete with its sub-
strate ATP were further verified by in vitro and in vivo anti-
bacterial assays. Eventually, we obtained 6 compounds
with antibacterial activity that may be used as novel drug
leads.
Commonly, the response regulator YycF and the histidine
kinase YycG are the only essential TCS for viability in B.
subtilis and S. aureus [10,12]. In S. pneumoniae, the VicR/K
TCS regulates the expression of several critical genes, such
as those encoding surface proteins and virulence factors
[21,33]. However, only the response regulator VicR was
found to be essential [20,34]. The signal transduction of
VicK was possibly bypassed by other TCS HKs [35]. VicK
has conserved ATP-dependent HATPase_c domains
accounting for autophosphorylation. Even non-cognate
HKs from other bacteria can phosphorylate the purified
VicR from S. pneumoniae [18]. In a previous study [36], the
MIC values of the lead compounds screened out by SBVS
targeting the YycG of S. epidermidis were almost equal to
the corresponding IC50 (for YycG') values, with a correla-
tion coefficient of 0.959, which suggested that inhibition
of 50% the YycG protein activity would interfere with the
growth of S. epidermidis. If this case is true in S. pneumo-
niae, the result that the MIC values of the lead-compounds
were far less than the corresponding IC50 values may be
explained as bypass effects of these compounds on other
HKs. In a word, these lead compounds are most likely
having a "cross-inhibition" on other HKs in S. pneumo-
niae, which can enhance their antibacterial effects,
although they were not verified in this study.
Although the VicK protein in S. pneumoniae can be homol-
ogous to YycG in other Gram-positive strains, such as S.
epidermidis,  Enterococcus faecalis and  S. aureus, different
strains generally have different characteristics of the
HATPase_c domain structure of HKs. These characteristics
will determine the binding specificity of the lead com-
pounds screened out by SBVS. Moreover, a different tem-
plate for homologous modeling and different parameters
for SBVS were used, which can guarantee the specificity of
the lead compounds binding to the VicK' discovered.
What's more, 23 compounds can inhibit the purified
VicK' protein activity by more than 50%, 6 of which dis-
played different degrees of antibacterial effects in vitro and
in vivo. Regretfully, the in vivo activities of these com-
pounds were not quite consistent with their correspond-
ing  in vitro activity, and some compounds displayed
obvious cytotoxicity, which would challenge our future
investigation. Moreover, it seems to be a paradox that
Three-dimensional structural binding modes of six potential  inhibitors to VicK' protein derived from the docking simula- tions Figure 8
Three-dimensional structural binding modes of six 
potential inhibitors to VicK' protein derived from the 
docking simulations. The loop covered on the pocket was 
shown in tube. Six compounds were shown in stick with dif-
ferent colors. Their binding conformations showed similar 
interaction modes in the inner pocket. The binding diversity 
was restrained by small space and hydrophobic characteris-
tic. By contrast, these structures bound in the outer pocket 
in various ways. This image was generated using the PyMol 
program http://www.pymol.org/.BMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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compound 4 have less bactericidal effects in the time- and
concentration-dependent antibacterial assays, but dem-
onstrated significant therapeutic effects in mice infected
by S. pneumoniae. However, due to the VicK' is not essen-
tial in S. pneumoniae, this chemical may have a possibility
to interrupt the invasion and virulence rather than cause
numerous death of the bacterium, which decreases the
selection pressure and contributes to the maintenance of
species diversity, thus reduces the emergence of drug-
resistant strains. Anyway, the subtle mechanisms need our
future work.
Conclusion
To summarize, we have successfully found out several
promising lead compounds for further drug development
in this study, which also can be used as inhibitors to
explore the mechanism of autophosphorylation by VicK
as well as other HKs. Important work in future would be
validation of their antibacterial effects in different strains
and structural modification for more effective derivatives
with less in vivo toxicity, and investigation into whether
they can bind to other ATP-dependent kinase is also nec-
essary.
Methods
Bacterial strains, media and reagents
S. pneumoniae (D39) ATCC 7466 was purchased from the
American Type Culture collection (ATCC, USA).S. pneu-
moniae D39 was grown in C + Y medium. Plasmids were
transformed into Escherichia coli (E. coli) strains that were
grown in Luria-Bertani (LB) broth. For selection of E. coli
transformants, kanamycin (50 mg/ml, final concentra-
tion) was added to the growth medium.
All compounds screened out in our study were purchased
from the SPECS Company in the Netherlands. Stock solu-
tions of the compounds were prepared in Dimethyl Sul-
foxide (DMSO). Other chemicals were purchased from
Sigma.
Bioinformatics analysis
Domain analysis was performed based on the SMART
database. The complete genome sequences of the S. pneu-
moniae strain ATCC 7466 were accessed from the National
center for Biotechnology information (NCBI) genome
database. For the homologous sequences with the VicK
HATPase_c domain of S. pneumoniae ATCC 7466, the Pro-
tein Data Bank (PDB) was searched by using the Blastp
program. ClustalX was used to align the protein
sequences.
3D structure modeling of the VicK HATPase_c domain
The sequence of S. pneumoniae VicK was retrieved from
GenBank (accession number: AAK75332.1). The
Align123 module in Insight II was used in the pairwise
sequence alignment. Using the secondary structure infor-
mation of Thermotoga maritima (PDB entry: 2c2a), the
sequence alignment was adjusted manually to obtain a
fine alignment for 3D structure construction. The 3D
model of the VicK HATPase_c domain was generated by
using the MODELLER module in Insight II. Several struc-
tural analysis programs such as Prostat and Profile-3D
were used to check the structure quality. The Prostat mod-
ule of Insight II was used to analyze the properties of
bonds, angles, and torsions. The profile-3D program was
used to check the structure and sequence compatibility.
Structure-based virtual screening
Structure-based virtual screening was performed as
described previously [36], with modification. Briefly, the
binding pocket of the VicK HATPase_c domain was used
as a target for screening the SPECS database by using the
docking approach. A primary screening was conducted by
using the program DOCK4.0. Residues within a radius of
4  around the ATP-binding pocket of the VicK HATPase_c
domain were used for constructing the grids for the dock-
ing screening. Subsequently, the 10,000 compounds with
the highest score as obtained by DOCK search were
selected for a second round docking by using the Auto-
dock 3.05 program, followed by our own filter of drug-
likeness to eliminate the non-drug-able molecules.
Finally, we manually selected 105 molecules according to
their molecular diversity, shape complementarities, and
potential to form hydrogen bonds in the binding pocket
of the VicK HATPase_c domain.
Molecular modeling of the interaction between inhibitors 
and the target protein
To determine the binding modes, Autodock3.05 was used
for automated docking analysis. The Lamarchian genetic
algorithm (LGA) was applied to deal with the protein-
inhibitor interactions. Some important parameters were
set as follows: the initial number of individuals in popu-
lation is 50; the elitism value is 1, which automatically
survives into nest generation. The mutation rate is 0.03,
which is a probability that a gene would undergo a ran-
dom change. The crossover rate, the probability of propor-
tional selection, is 0.80. Every compound was set to have
10 separated GA runs and finally 10 conformations would
be generated. The conformations were clustered automat-
ically and the conformation with minimum binding free
energy in the cluster with minimum RMSD value was
selected as the representative conformation of the inhibi-
tor.
Cloning, expression and purification of the VicK protein
The VicK gene fragment containing the cytoplasmic signal
domains (the HATPase_c and HisKA domain) of VicK
(coding 200–449 aa) was amplified by PCR. The
upstream and the downstream primers were 5'-BMC Microbiology 2009, 9:129 http://www.biomedcentral.com/1471-2180/9/129
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CGGGATCCGAGCAGGAGAAGGAAGAAC-3' and 5'-
CGCTCGAGGTCTTCTACTTCATCCTCCCA-3' respec-
tively. Subsequently, the fragment was digested with EcoR
I and Xho I (TaKaRA, Japan) and ligated into the corre-
sponding sites of pET28a to obtain a recombinant plas-
mid pET28/VicK'. After being transformed into E. coli
strain BL21 (DE3), this recombinant plasmid was induced
to express the protein of VicK' by 0.2 mM isopropyl-1-
thio-b-D-galactopyranoside (IPTG) at 24°C for 20 hours.
Cells were harvested and sonicated, and then the debris
was removed by centrifugation. The fraction containing
the cytoplasmic domain was isolated from the superna-
tant solution through a His-tagged column, with a purity
of more than 95%, as assessed by gel electrophoresis and
Coomassie Blue staining.
Inhibition assay for the ATPase activity
The inhibitory activity of the compounds for the ATPase
activity of the VicK' protein was measured using the
Kinase-Glo™ Luminescent Kinase Assay (Promega, Madi-
son, USA). Briefly, 6 mg purified VicK' protein was pre-
incubated with a series of dilutions of compounds in a
reaction buffer containing 40 mM Tris-HCl (pH 7.5), 20
mM MgCl2 and 0.1 mg/ml BSA, at room temperature for
10 min. Then 5 mM ATP was added for another incubation
of 10 min at room temperature, and Kinase-Glo™ Reagent
was added to detect the rest amount of ATP, as reflected by
luminescence intensity (Lu). In parallel, the VicK' protein
with no addition of compounds was used as control and
ATP only was used as blank. The rate of inhibiting protein
phosphorylation (Rp) by the compounds was calculated
by the following equation: Rp = (Lucompound - Lucontrol)/
(Lublank - Lucontrol) × 100%. IC50 (the concentration of
inhibiting 50% VicK' protein autophosphorylation) was
calculated by using the SPSS 11.0 software.
Minimal inhibitory concentration (MIC) and minimal 
bactericidal concentration (MBC) assays
MIC assays for the antibacterial activities of the com-
pounds were performed according to the broth micro-
dilution (in 96-well plate) methods of the Clinical and
Laboratory Standards Institute (CLSI) of America. The
Minimal Bactericidal Concentration (MBC) was obtained
by sub-culturing 200 ml from each negative (no visible
bacterial growth) well in the MIC assay which were then
plated onto Columbian blood plates. The plates were
incubated at 37°C for 24 hours, and the MBC was defined
as the lowest concentration of substance which produced
subcultures growing no more than five colonies on each
plate. Each assay was repeated at least three times.
Time- and concentration-dependent curve
S. pneumoniae strains ATCC7466 were grown at 37°C in C
+ Y medium till OD550 reaching 0.1. Then 200 ml of the
suspending bacteria was extracted into the wells of a 96-
well plate for incubation at 37°C with the additions of 3
different dilutions of the 6 compounds. Subsequently, the
plate was detected by spectrophotometer per hour for
drawing the time- and concentration-dependent curve. All
samples were assayed in triplicate, and each assay was
repeated at least three times.
In vitro cytotoxicity
Cytotoxicity of the antibacterial compounds on cultured
Vero cell was measured by using the Cell Proliferation Kit
I (MTT) (Sigma). Briefly, a series of dilution of the com-
pounds were added into the medium, containing 1% of
DMSO, to culture Vero cell. Cytotoxicity of the different
concentration of chemicals was determined according to
the kit protocol. Each assay was performed in quadrupli-
cate and repeated three times. The results were converted
to percentages of the control (cells only treated with 1%
DMSO) and CC50 (concentrations that produce a 50%
cytotoxicity effect on Vero cell) was calculated by using
the SPSS 11.0 software.
In vivo assays
Male and female BALB/c mice, aged 6–8 weeks (approx.
18–20 g), were used to evaluate the in vivo effects of the
compounds. Briefly, these mice were randomly assigned
to 8 groups (10-12 per group, half in each sex): 6 com-
pound-treated groups, one negative control and one pos-
itive control. All the mice were administrated with 100 ml
suspended S. pneumoniae strain ATCC 7466 (5 × 103 CFU/
ml in phosphate buffered saline) by intraperitoneal injec-
tion route. Compounds (1–6) were diluted to the concen-
tration of MIC respectively (1.27 mg/kg/d, 0.65 mg/kg/d,
1.13 mg/kg/d, 2.32 mg/kg/d, 1.27 mg/kg/d, 0.014 mg/kg/
d, respectively) with normal sodium and 200 ml was
administered by vena caudalis route after infection. Two
control groups were administered with 200 ml normal
sodium (negative control) and penicillin (0.42 mg/kg/d,
positive control) respectively by the same injection route.
Treatments were continued 3 times a day for 3 consecutive
days, and these levels of chemicals caused few toxic influ-
ences on normal mice. The results are expressed as cumu-
lative survival rates over the following 8-day observation.
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